Fig. 4
From: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
CD8+ increase and CD4+FoxP3+ decrease in glioma after NIC treatment. a Immunostaining of CD8+ T cells in tumors treated with PBS, a-CTLA-4, a-PD-1, P/a-CTLA-4, P/a-PD-1, and P/a-CTLA-4+P/a-PD-1. Arrows indicate CD8+ lymphocytes (magenta) that increase after NIC treatment. Scale bar on bottom right panel applies to all other images. b Treatments with P/a-PD-1 and P/a-CTLA-4+P/a-PD-1 result in a statistically significant increase of CD8+ lymphocytes inside the tumor. 8499 cells are analyzed in tumors from 24 mice representing six treatment groups, N = 4 per group. Data are mean ± SEM. **p < 0.01; ***p < 0.001; ****p < 0.0001 (one-way ANOVA with Sidak’s posttest). c Immunostaining of CD4+FoxP3+ T cells in tumors treated with PBS, a-CTLA-4, a-PD-1, P/a-CTLA-4, P/a-PD-1, and P/a-CTLA-4+P/a-PD-1. Arrows indicate CD4+FoxP3+ lymphocytes that are decreased after NIC treatment. CD4 staining is green, FoxP3 staining is red, DAPI nuclear staining is blue. d P/a-PD-1 and P/a-CTLA-4+P/a-PD-1 treatments significantly decrease the number of CD4+FoxP3+ lymphocytes in the tumor. 9898 cells are analyzed in tumors from 24 mice representing six treatment groups, N = 4 per group. **p < 0.01; ***p < 0.001; ****p < 0.0001 (one-way ANOVA with Sidak’s posttest)
